Premium
CTLA‐4 gene polymorphisms and natural soluble CTLA‐4 protein in psoriasis vulgaris
Author(s) -
Łuszczek W.,
Kubicka W.,
Jasek M.,
Baran E.,
Cisło M.,
Nockowski P.,
ŁuczywoRudy M.,
Wiśniewski A.,
Nowak I.,
Kuśnierczyk P.
Publication year - 2006
Publication title -
international journal of immunogenetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.41
H-Index - 47
eISSN - 1744-313X
pISSN - 1744-3121
DOI - 10.1111/j.1744-313x.2006.00600.x
Subject(s) - single nucleotide polymorphism , genotype , psoriasis , haplotype , ctla 4 , allele , genetics , gene , biology , restriction fragment length polymorphism , polymerase chain reaction , immunology , microbiology and biotechnology , t cell , immune system
Summary CTLA‐4 molecule is an important inhibitor of T‐lymphocyte activation. Several single nucleotide polymorphisms (SNPs) in the CTLA‐4 gene were found, and their associations with many human diseases were described. So far, however, such studies have not been performed in psoriasis vulgaris in Caucasoids. Therefore, we examined the distribution of three CTLA‐4 SNPs: −1147C/T, −318C/T and +49 A/G in 116 patients with psoriasis vulgaris and 123 healthy blood donors using the polymerase chain reaction–restriction fragment length polymorphism method. For all three SNPs, the frequencies of alleles, genotypes and three‐point haplotypes were very similar in patients and controls, suggesting no contribution of these genetic variants to psoriasis.